Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitor plus statin therapy for CT-FFR in borderline coronary lesions
ChiCTR2200055718Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab, atorvastatin and rosuvastatin in coronary arteriosclerosis (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Change in CT-FFR value 20 mm distal to borderline coronary lesion. Started Jan 2022; status: recruiting.
02
Drugs
evolocumabatorvastatinrosuvastatin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200055718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055718.